Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of some unusual options trading on Monday. Traders acquired 827 call options on the stock. This represents an increase of approximately 934% compared to the average volume of 80 call options.

In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the sale, the director now owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $10.39, for a total value of $103,900.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,382 shares of company stock worth $533,371. Company insiders own 14.71% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Swiss National Bank raised its holdings in Karyopharm Therapeutics by 39.2% in the 2nd quarter. Swiss National Bank now owns 56,850 shares of the company’s stock worth $514,000 after purchasing an additional 16,000 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Karyopharm Therapeutics by 4.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after purchasing an additional 3,762 shares during the period. Candriam Luxembourg S.C.A. raised its holdings in Karyopharm Therapeutics by 16.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after purchasing an additional 72,000 shares during the period. Vanguard Group Inc. raised its holdings in Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after purchasing an additional 384,658 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Karyopharm Therapeutics by 17.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock worth $2,930,000 after purchasing an additional 47,699 shares during the period. Hedge funds and other institutional investors own 60.92% of the company’s stock.

Several research firms have weighed in on KPTI. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Royal Bank of Canada began coverage on Karyopharm Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $14.00 price target on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, September 20th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Karyopharm Therapeutics has a consensus rating of “Buy” and an average target price of $17.33.

Shares of Karyopharm Therapeutics (KPTI) opened at $9.66 on Thursday. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. analysts anticipate that Karyopharm Therapeutics will post -2.58 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics Target of Unusually High Options Trading (KPTI)” was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/12/14/karyopharm-therapeutics-target-of-unusually-high-options-trading-kpti.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.